Company / SG&A Expense
KESTRA MEDICAL TECHNOLOGIES, LTD. SG&A Expense History
FY2023-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$114.9M
FY2024
5-year range
$69.9M / $114.9M
FY2023-FY2024
Trend
+64.3%
vs FY2023
Sector context
#131 of 158
Health Care
What the data says
KESTRA MEDICAL TECHNOLOGIES, LTD.'s sg&a expense of $115M is lower than 83% of companies in the Health Care sector (FY2024).
Based on SEC 10-K filings.
$115M in FY2024.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 17% in Health CareTop 17% of 158This company $114.9M Sector average $175.9B
▼
-99.9% below sector average
Key checks
Key Insights
- In FY2024, sg&a expense increased 64.3% year-over-year.
- Ranks #131 out of 158 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -0.01 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $114.9M | +64.3% |
| FY2023 | $69.9M | - |
As of FY2024 · SEC 10-K · Updated Mar 29, 2026